Malaysian Experts Issue Consensus on Detecting and Treating Diabetic Nerve Damage

A panel of eleven Malaysian endocrinologists has published a new expert consensus offering practical, country-specific recommendations for identifying, evaluating, and pharmacologically managing diabetic sensorimotor polyneuropathy (DSPN), the most common form of diabetic peripheral neuropathy. The consensus, published open access in Diabetes Therapy, produced 61 final statements covering screening, diagnosis, sensory examination, and treatment, and was explicitly designed to fit the realities of Malaysian healthcare, an upper middle-income setting in Southeast Asia where the condition remains substantially underdiagnosed and undertreated. The panel’s central message is stark: clinicians should not wait for pain or other symptoms before assessing patients, because nerve damage can progress silently to complete sensory loss, foot ulceration, and lower-limb amputation.

DSPN is a chronic, progressive, and symmetric nerve disorder driven by sustained hyperglycemia, oxidative stress, and ischemic microvascular injury, affecting the longest nerve fibers first in a length-dependent pattern. It manifests as reduced or absent sensation, numbness, paraesthesia, imbalance, and in some patients neuropathic pain described as burning or electric-shock sensations in the feet and legs. Diabetic peripheral neuropathy affects an estimated 30 to 50 percent of people with diabetes globally, and local Malaysian studies suggest a similar prevalence. Crucially, the condition is often asymptomatic in its early stages, and the absence of painful symptoms does not exclude clinically important sensory deficits, a fact that underpins much of the panel’s guidance.

The clinical stakes extend well beyond the feet. Diabetic peripheral neuropathy is a strong predictor of serious systemic outcomes, including increased cardiovascular morbidity and all-cause mortality. In the ACCORD trial, a history of neuropathy was identified as the most significant predictor of mortality among patients with type 2 diabetes undergoing intensive glycemic control, while the DIAD study found that both sensory deficits and neuropathic pain independently predicted cardiac death or nonfatal myocardial infarction. Population-level data from the United States have even shown peripheral neuropathy to be an independent predictor of mortality among individuals without diabetes. The socioeconomic burden is also substantial, encompassing chronic pain, functional disability, hospitalization, wound care, and lost work productivity.

The gap between disease prevalence and clinical recognition in Malaysia is illustrated by a cross-sectional study in two urban community clinics, in which 49.9 percent of patients with diabetes had positive Neuropathy Symptoms Score results but only 0.2 percent carried a diagnosis of diabetic peripheral neuropathy. A survey of clinicians in Southeast Asia similarly found inadequate screening for the condition and low treatment priority for painful neuropathy compared with glycemic control, kidney function, and lipid management. To close this gap, the panel adapted its recommendations from the 2022 International Consensus on DSPN, the American Diabetes Association Standards of Care in Diabetes 2026, the 2020 Malaysian Clinical Practice Guidelines on type 2 diabetes, and the Malaysian Association for the Study of Pain neuropathic pain guideline. Sixty proposed statements were circulated for anonymous pre-meeting voting, with consensus defined as at least 80 percent agreement; 48 statements reached that threshold, and the remainder were revised during an in-person meeting in April 2026, ultimately yielding 61 approved statements.

On screening, the panel recommends annual assessment for all individuals with diabetes as a minimum standard of care, reflecting the insidious natural history of DSPN. The panel also emphasized extending screening to people with prediabetes, citing evidence that small-fiber neuropathy and early sensory deficits can appear before hyperglycemia reaches diabetic thresholds, particularly when metabolic syndrome components such as obesity, dyslipidemia, and insulin resistance are present. Clinical examination is central and should not be deferred until patients report symptoms. Assessment should query both painful descriptors such as burning, tingling, painful cold, or electric-shock sensations and non-painful complaints such as numbness or imbalance, but symptoms alone should never confirm or exclude the diagnosis, since objective sensory abnormalities may be present in asymptomatic individuals.

For diagnosis, the panel set a minimum clinical criterion of bilateral impairment in vibration perception and/or pin-prick sensation in the feet, consistent with the typical symmetric, length-dependent, stocking-and-glove distribution of the disease. Clinicians should perform at least two different bedside tests, drawing on monofilament testing, vibration perception, pin-prick discrimination, temperature differentiation, and ankle reflex assessment; combining modalities in this way raises diagnostic sensitivity for diabetic peripheral neuropathy to approximately 87 percent according to cited studies. Loss of protective sensation, which sharply increases the risk of foot trauma and ulceration, can be assessed with the 10-g monofilament applied to standard plantar sites, a 128-Hz tuning fork placed over the hallux, or simple tactile evaluation with the clinician’s index finger. Validated questionnaires such as DN4, ID Pain, and PainDETECT, the latter available in a locally validated Malay version, can complement but not replace objective examination.

The panel addressed several contested areas with notable caution. Point-of-care devices such as DPNCheck, which measures sural nerve conduction, and Sudoscan, which measures electrochemical skin conductance, were judged to lack sufficient evidence of added diagnostic value over careful history and bedside examination; concerns include variability in normative values, diagnostic specificity of skin conductance measures, and substantial manufacturer involvement in parts of the Sudoscan literature, so neither device is recommended for routine screening. The Ipswich Touch Test, which requires no equipment, was retained as an adjunct for rural or primary care settings with limited resources, despite unestablished predictive accuracy for foot ulceration. Because diabetic neuropathy is a diagnosis of exclusion, the panel also outlined differential diagnoses including vitamin B12 deficiency, particularly with long-term metformin use, alcohol and toxin exposure, hypothyroidism, kidney disease, infections, inflammatory neuropathies, and inherited conditions, with red flags such as marked asymmetry, rapid progression, or predominant motor involvement warranting neurologist referral.

On treatment, the consensus places optimization of glycemic control and lifestyle interventions at the foundation, while acknowledging nuanced evidence: the DCCT and EDIC studies demonstrated reductions in DSPN risk of up to 78 percent in type 1 diabetes, whereas large randomized trials in type 2 diabetes show a more modest 5 to 9 percent relative risk reduction in neuropathy incidence. The Look AHEAD trial found no significant change in objective neuropathy scores with intensive lifestyle intervention but did show improvement in patient-reported symptoms. For painful DSPN, first-line pharmacotherapy centers on gabapentinoids such as pregabalin and gabapentin, serotonin-norepinephrine reuptake inhibitors such as duloxetine, and tricyclic antidepressants such as amitriptyline, selected according to comorbidities, side-effect profiles, interactions, cost, and patient preference. If an initial medication fails or is intolerable, a different class should be tried, and combination therapy may be considered for partial response, though supporting data are limited. Alpha-lipoic acid, which has shown short-term symptom improvements at 600 mg/day in some studies, and benfotiamine are positioned strictly as adjunctive options in selected patients, not as disease-modifying therapies, and vitamin B12 supplementation is reserved for confirmed deficiency.

Two positions stand out for their firmness. First, the panel strongly discourages opioids, including tramadol, citing risks of dependence, withdrawal, serotonin syndrome, tolerance, addiction, respiratory depression, and overdose, alongside lacking evidence of long-term benefit in chronic neuropathic pain; tramadol is confined to rare, short-term use of less than three months in carefully selected patients with severe acute pain unresponsive to other agents, with specialist referral and a defined end point. Second, the panel endorsed a structured step-down strategy: if pain relief is maintained for at least six months, gradual dose reduction should be considered, with treatment resumed at the lowest effective dose if symptoms recur. Non-pharmacological adjuncts were treated with similar restraint, as acupuncture showed clinically meaningful improvements in symptom and deficit scores in the ACUDPN randomized trial persisting at least 16 weeks, but overall evidence remains limited; evidence for transcutaneous electrical nerve stimulation was judged inconclusive by the 2025 NeuPSIG review, and spinal cord stimulation is restricted to severe refractory cases after specialist multidisciplinary assessment.

The panel was candid about its limitations. The consensus was developed through expert adaptation of existing guidance rather than a de novo systematic review, without a formal evidence-grading framework such as GRADE, and the panel consisted solely of Malaysian endocrinologists, omitting neurologists, podiatrists, and primary care physicians whose perspectives might have enriched recommendations on atypical neuropathy, foot-risk assessment, and frontline implementation. The recommendations reflect expert opinion within a single-country setting and have not undergone external validation. Even so, the document fills a significant national gap by translating global best practices, including alignment with the ADA, the American Academy of Neurology, the International Working Group on the Diabetic Foot, and NeuPSIG guidance, into accessible, context-sensitive recommendations, with the explicit aim of improving care consistency, reducing DSPN-related complications, and enhancing quality of life for the many Malaysians living with this silent but consequential complication of diabetes.

Subject of Research: Expert consensus recommendations for screening, diagnosis, and pharmacological management of diabetic sensorimotor polyneuropathy in Malaysia

Article Title: A Malaysian Expert Consensus on The Identification, Evaluation, and Pharmacological Management of Diabetic Sensorimotor Polyneuropathy

Article References: Lim, L.-L., Foo, S.-H., Abdul Ghani, R., Ibrahim, L., Wahab, N. A., Mohamed, W. M. I. W., Lim, S.-C., Mustafa, N., Hew, F.-L., Hussein, Z., & Chan, S.-P. (2026). A Malaysian Expert Consensus on The Identification, Evaluation, and Pharmacological Management of Diabetic Sensorimotor Polyneuropathy. Diabetes Therapy. https://doi.org/10.1007/s13300-026-01927-8

Image Credits: AI Generated

DOI: 10.1007/s13300-026-01927-8

Keywords: diabetic sensorimotor polyneuropathy, diabetic peripheral neuropathy, Malaysia, expert consensus, screening, 10-g monofilament, neuropathic pain, pregabalin, duloxetine, alpha-lipoic acid, glycemic control, foot ulceration